Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis-Reference-Cited by-同舟云学术

Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis

Published:2021-06-01 Issue:6 Volume:157 Page:676
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Loft Nikolai¹²,Egeberg Alexander¹³,Rasmussen Mads Kirchheiner⁴,Bryld Lars Erik⁵,Nissen Christoffer Valdemar³,Dam Tomas Norman⁶,Ajgeiy Kawa Khaled⁷,Iversen Lars⁴,Skov Lone¹²

Affiliation:

1. Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

2. Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, Hellerup, Denmark

3. Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark

4. Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark

5. Department of Dermatology, Zealand University Hospital, Roskilde, Denmark

6. Dermatology Clinic, Nykoebing Falster, Denmark

7. Department of Dermatology, Odense University Hospital, Odense, Denmark

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2778168/jamadermatology_loft_2021_oi_210006_1623774337.15374.pdf

Reference36 articles.

2. Biosimilars in dermatology: the wind of change.;Constantin;Exp Ther Med,2019

3. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.;Egeberg;Br J Dermatol,2018

4. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.;Glintborg;Ann Rheum Dis,2017

5. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.;Glintborg;Ann Rheum Dis,2019

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?;Journal of Health Economics and Outcomes Research;2024-03-25

2. Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?;Journal of Health Economics and Outcomes Research;2024-03-25

3. Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study;Journal of Psoriasis and Psoriatic Arthritis;2024-02-19

4. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases;Advances in Therapy;2023-12-19

5. Biosimilars in Dermatology Review;Journal of Psoriasis and Psoriatic Arthritis;2023-11-03